Clinical Trial Details

Overview

Research Study Summary

Phase 3B/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to a Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis

Purpose

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

To Learn more

CW ID: 203056
Date Last Changed: March 8, 2016

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
50 and up
Overall Status
Recruiting
Lead Sponsor
Pfizer
Facility Type
N/A

Contact

Gail Lewis
University of South Florida - Morsani Center for Advanced Healthcare
13330 USF Laurel Drive
Tampa, FL 33612
Phone: (813)974-9509

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.